Sign in
Taking people in United StatesNo phase

Sinus Disease and Smell in Young Children With Cystic Fibrosis

Observes sinus disease and smell in children with cystic fibrosis taking modulator drugs.

Key facts

Who runs it
University of California, Los Angeles
Where
Aurora, Charlottesville, Cincinnati, Colchester, Iowa City, and Kansas City, United StatesSee the 6 sites
Trial code
Registry title
Sinus Disease in Young Children With Cystic Fibrosis
Status
Recruiting
People taking part
80 people, planned
Started
12 Apr 2023
Expected to end
30 Jun 2029
Type of study
Observational, 2 groups
Treatments tested
  • Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 2 to 8 with cystic fibrosis. One group is about to start modulator therapy; the other group is not taking it.

Age
2 to 8 years old at the first study visit
Sex
All sexes
Earlier treatment
Children in the modulator group must not have used ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 180 days before the first visit.
Biomarker or test result
Modulator group: a CFTR mutation that fits the approved use of ivacaftor or elexacaftor/tezacaftor/ivacaftor. Control group: a CFTR mutation that rules out this therapy, or a clinical decision not to start it.

Main reasons for not taking part

  • Investigational drug in the 28 days before the first study visit
  • Ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 180 days before the first study visit
  • Long-term oral corticosteroids in the 28 days before the first study visit
  • Sinus surgery in the 180 days before the first study visit

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • HEMT Group:
  • Children with documentation of a CF diagnosis
  • Age 2-8 years old at first study visit
  • CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor)
  • Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT; Non-HEMT/Control Group:
  • Children with documentation of a CF diagnosis
  • Age 2-8 years at first study visit
  • Ineligible for highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor) based on CFTR mutation or clinical decision not to initiate HEMT if eligible

Who cannot take part

  • Use of an investigational drug within 28 days prior to the first study visit
  • Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 180 days prior to and including the first study visit
  • Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit
  • Sinus surgery within 180 days prior to the first study visit
  • For Both Groups:

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 8 years old?

Where in United States

  • Children's Hospital ColoradoAurora, United StatesContact: Edith Zemanick, MDTaking people
  • University of VirginiaCharlottesville, United StatesContact: Jaime Mata, MS, PhDTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Jason Woods, PhDTaking people
  • University of VermontColchester, United StatesContact: Jillian S Sullivan, MDTaking people
  • University of IowaIowa City, United StatesContact: Sean B Fain, PhDTaking people
  • University of Kansas Medical CenterKansas City, United StatesContact: Michael Lewis, MDTaking people

About the trial

What the trial wants to find out

This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.

The 2 groups in the trial

  • HEMT Group

    Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the non-HEMT group of this study may enroll into the HEMT cohort if they become eligible for these CFTR modulator therapies and plan to start them.

    Treatment: Ivacaftor or elexacaftor/tezacaftor/ivacaftor

  • Non-HEMT/Control Group

    Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Sinus Disease in Young Children With Cystic Fibrosis
Plain-language title
Sinus Disease and Smell in Young Children With Cystic FibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06191640, who can take part
Publications
Record updated
10 September 2026